Medical University of Sofia
Welcome,         Profile    Billing    Logout  
 3 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fazeli, Pouneh K
RESCUE, NCT05307328: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
NCT03875378: Transdermal Estrogen in Women With Anorexia Nervosa

Recruiting
2
66
US
Transdermal estrogen, Placebos
Pouneh K. Fazeli, MD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Anorexia Nervosa
09/25
12/25
NCT05722873: The Metabolic Effects of Intermittent Fasting

Recruiting
N/A
90
US
Fasting arm, Weight maintenance, Counseling
University of Pittsburgh
Normal and Overweight Individuals at High-risk of Diabetes
06/28
06/28
Boyanova, L
Hp-EuReg, NCT02328131: European Registry on the Management of Helicobacter Pylori Infection

Recruiting
N/A
10000
Europe, RoW
Javier P. Gisbert
H. Pylori Infection
12/24
12/24
Kamenov, Zdravko
RESCUE, NCT05307328: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
ACSPIRE, NCT05436639: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Active, not recruiting
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
12/25
Vassileva, Snejina
BALLAD+, NCT05681481 / 2021-003063-10: A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Recruiting
3
160
Europe, Japan, US, RoW
efgartigimod PH20 SC, Prednisone
argenx, argenx BV
Bullous Pemphigoid
01/26
03/26
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Recruiting
2
99
Europe, Canada, US, RoW
Placebo/Daxdilimab, Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus
07/24
12/24
NCT05534776: Validation of 5-Point Investigator Global Assessments for Pemphigus

Recruiting
N/A
40
Europe, RoW
Investigator Global Assessments (IGAs)
Premier Specialists, Australia
Pemphigus
08/23
08/23
Drenovska, Kossara
NCT05534776: Validation of 5-Point Investigator Global Assessments for Pemphigus

Recruiting
N/A
40
Europe, RoW
Investigator Global Assessments (IGAs)
Premier Specialists, Australia
Pemphigus
08/23
08/23
Todorova, Ginka
RESCUE, NCT05307328: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25

Download Options